Shire has been presented with a prestigious accolade from the European Organisation for Rare Diseases (Eurordis) for its pioneering work in developing new therapies for uncommon illnesses.
The pharmaceutical company has been granted the Eurordis Company Award for its commitment to working with patient groups in order to create new drugs, as well as its efforts to make the products as accessible as possible across the EU.
It coincided with Rare Disease Day, a global event designed to raise awareness of rare conditions and the healthcare challenges faced by those affected, such as the difficulty of obtaining the relevant diagnoses, support, therapies and information.
Sylvie Gregoire, president of Shire Human Genetic Therapies, said the company looks forward to collaborating with Eurordis further in the future.
She added: "This award embodies the spirit of our organisation - every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' lives."
Last month, the European Medicines Agency granted Shire approval to use its new manufacturing site in Lexington, Massachusetts to expand the global supply of Vpriv, its treatment for type 1 Gaucher disease.